After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...

I plan to diversify my REIT-heavy portfolio by systematically allocating to four dividend-focused ETFs in 2026. Read about ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from ...

A look at news events in April 2025: A look at news events in April 2025: ...

Andrew Bloomenthal has 20+ years of editorial experience as a financial journalist and as a financial services marketing writer. David Kindness is a Certified Public Accountant (CPA) and an expert in ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Class 10 English Error Correction Exercise: The CBSE Class 10 English exam includes a dedicated section of grammar questions that carry high weightage. Among them ...

Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.